Swiss National Bank Has $2.36 Million Stock Position in NeoGenomics, Inc. $NEO

Swiss National Bank reduced its holdings in NeoGenomics, Inc. (NASDAQ:NEO) by 1.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 248,700 shares of the medical research company’s stock after selling 3,400 shares during the period. Swiss National Bank owned about 0.19% of NeoGenomics worth $2,360,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of NEO. CWM LLC increased its holdings in shares of NeoGenomics by 42.6% in the 1st quarter. CWM LLC now owns 6,299 shares of the medical research company’s stock valued at $60,000 after purchasing an additional 1,883 shares during the period. Moors & Cabot Inc. purchased a new position in NeoGenomics during the first quarter valued at approximately $95,000. Teacher Retirement System of Texas acquired a new position in NeoGenomics in the 1st quarter valued at approximately $178,000. Sherbrooke Park Advisers LLC purchased a new stake in NeoGenomics in the 4th quarter worth approximately $183,000. Finally, Bailard Inc. acquired a new stake in shares of NeoGenomics during the 1st quarter valued at $183,000. Hedge funds and other institutional investors own 98.50% of the company’s stock.

Insider Buying and Selling

In other news, Director Michael Aaron Kelly purchased 5,000 shares of the company’s stock in a transaction dated Tuesday, May 27th. The shares were bought at an average price of $7.60 per share, with a total value of $38,000.00. Following the completion of the transaction, the director directly owned 5,000 shares in the company, valued at $38,000. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.40% of the stock is currently owned by company insiders.

NeoGenomics Stock Performance

Shares of NASDAQ NEO opened at $6.61 on Friday. The business’s 50-day simple moving average is $6.57 and its 200-day simple moving average is $8.44. The company has a debt-to-equity ratio of 0.40, a quick ratio of 3.58 and a current ratio of 3.92. NeoGenomics, Inc. has a 52 week low of $4.72 and a 52 week high of $19.11. The firm has a market cap of $853.88 million, a price-to-earnings ratio of -8.16 and a beta of 1.54.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on NEO shares. William Blair reaffirmed a “market perform” rating on shares of NeoGenomics in a research note on Tuesday, July 29th. The Goldman Sachs Group dropped their target price on NeoGenomics from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, April 30th. Wall Street Zen upgraded NeoGenomics from a “sell” rating to a “hold” rating in a report on Tuesday, May 13th. Leerink Partners cut NeoGenomics from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $25.00 to $9.00 in a research note on Wednesday, April 30th. Finally, Leerink Partnrs downgraded NeoGenomics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 30th. Four research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat, NeoGenomics currently has a consensus rating of “Hold” and a consensus target price of $12.75.

NeoGenomics Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.